期刊文献+

IFNγ释放试验评价水痘减毒活疫苗的细胞免疫效果 被引量:3

Evaluation of cell-mediated immunity of live attenuated varicella vaccine by IFNγ release assay
原文传递
导出
摘要 目的应用IFNγ释放试验评价水痘减毒活疫苗的细胞免疫效果。方法利用IFNγELISA定量试剂盒检测不同灭活抗原(热灭活、紫外灭活、甲醛灭活)刺激、不同孵育时间(24、48、72 h)、不同个体(12人接种水痘减毒活疫苗前后)对IFNγ释放水平的影响。结果紫外灭活方式制备的刺激抗原及新鲜全血与刺激抗原共孵育48 h,IFNγ释放水平最高;12人接种疫苗后全血中IFNγ释放水平均有不同程度提高,接种前后几何平均值(GMT)分别为6.13和234.75 pg/ml,增长倍数和GMT值在个体间均存在较大差异。结论 IFNγ释放试验操作简便、快速,可定量,适用于水痘疫苗细胞免疫效果的评价。 Objective To evaluate the cell-mediated immunity(CMI)of live attenuated varicella vaccine by interferon γ(IFNγ)release assay.Methods The effect of various inactivated antigens(heat-inactivated,ultraviolet-inactivated and formaldehyde-inactivated),incubation time(24,48 and 72 h)and individuals(12 volunteers before and after immunization with live attenuated varicella vaccine) on the release level of IFNγ were evaluated by quantitative ELISA kit for IFNγ.Results The IFNγ release levels stimulated by ultraviolet-inactivated antigen and by fresh blood co-incubated with ultraviolet-inactivated antigen for 48 h were the highest.The GMTs of IFNγ in blood of 12 volunteers before and after immunization were 6.13 and 234.75 pg/ml respectively.However,the GMTs and their increasing folds showed significant difference in various individuals.Conclusion IFNγ release assay was simple,rapid and quantitative,which was suitable for the evaluation of CMI of varicella vaccine.
出处 《中国生物制品学杂志》 CAS CSCD 2016年第7期744-747,共4页 Chinese Journal of Biologicals
关键词 干扰素γ释放试验 水痘减毒活疫苗 细胞介导免疫 Interferon γ release assay Live attenuated varicella vaccine Cell-mediated immunity
  • 相关文献

参考文献14

  • 1高睿迪,杨慧兰,刘仲荣,樊建勇.水痘-带状疱疹病毒研究进展[J].中国麻风皮肤病杂志,2014,30(4):216-219. 被引量:14
  • 2伊兴旭,甘霖,陈敬贤,王明丽.水痘-带状疱疹病毒疫苗的评价与研究进展[J].微生物与感染,2014,9(4):256-260. 被引量:16
  • 3LEVIN M J, OXMAN M N, ZHANG J H, et al. Varicella- zoster virus specific immune responses in elderly recipients of a herpes zoster vaccine [J]. J Infect Dis, 2008, 197 (6): 825- 835.
  • 4WEINBERG A, LEVIN M J. VZV T cell-mediated immunity [J]. Curr Top Microbiol Immunol, 2010, 342: 341-357.
  • 5OTANI N, YAMANISHI K, SAKAGUCHI Y, et ol. Varieella- zoster virus-specific cell-mediated immunity in subjects with herpes zoster [J]. J Immunol Methods, 2012, 377 (1-2): 53- 55.
  • 6WATANABE D, OTANI N, SUZUKI S, et ol. Evaluation of VZV-specific cell- mediated immunity in adults infected with HIV-1 by using a simple IFN-γrelease assay [J]. J Med Virol, 2013, 85 (8): 1313-1320.
  • 7李映波,姜述德.水痘-带状疱疹病毒及其疫苗研究进展[J].云南大学学报(自然科学版),2007,29(S3):368-372. 被引量:2
  • 8OTANI N, BABA K, OKUNO T. Interferon-γ release assay: a simple method for detection of varicella-zoster virus-specific cell-mediated immunity [J]. J Immunol Methods, 2009, 351 (1-2): 71-74.
  • 9KEMPISTY A, BIALAS-CHROMIEC B, BORKOWSKA D, et al. Interferon gamma reease assays based on M. tuberculosis- specific antigens in sarcoidosis patients [J]. Pneumonol Alergol Pol, 2015, 83 (2): 126-134.
  • 10TERADA K, ITOH Y, FUJII A, et al. Varicella-zoster virus- specific, cell-mediated immunity with interferon-gamma release assay after vaccination of college students with no or interme- diate IgG antibody response [J]. J Med irol, 2015, 87 (2): 350-356.

二级参考文献52

  • 1Lfinnroth K, Corbett E, Golub J, et a!. Systematic screening for active tuberculosis: rationale, definitions and key considerations [J]. Int J Tuberc Lung Dis, 2013, 17(3):289-298.
  • 2Behr MA, Wilson MA, Gill WP, et ol. Comparative genomics of BCG vaccines by whole-genome DNA microarray[J]. Science, 1999, 284(5419):1520-1523.
  • 3Mazurek GH, Jereb J, Lobue P, et all. Guidelines for using theQuantiFERON-TB Gold test for detecting Mycobacterium tubercu- losis infection, United States[J]. MMWR Recomm Rep, 2005, 54 (RR-15):49-55.
  • 4Lalvani A.Diagnosing tuberculosis infection in the 21st century:new tools to tackle an old enemy[J ]. Chest, 2007, 131(6): 1898-1906.
  • 5Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a meta analysis[J]. Chest, 2010, 137(4):952-968.
  • 6Connell TG, Ritz N, Paxton GA, eta/. A three-way comparison of tuberculin skin testing, QuantiFERON-TB gold and T-SPOT.TB in children[J]. PLOS One, 2008, 3(7):e2624.
  • 7Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster [J]. J Clin Virol, 2010, 48(Suppl 1): S2-S7.
  • 8Oliver SL, Sommer MH, Reichelt M, Rajamani J, Vlaycheva-Beisheim L, Stamatis S, Cheng J, Jones C, Zehnder J, Arvin AM. Mutagenesis of varicella-zoster virus glycoprotein I (gI) identifies a cysteine residue critical for gE/gI heterodimer formation, gI structure, and virulence in skin cells [J]. J Virol, 2011, 85(9): 4095-4110.
  • 9Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapeli:re P, Vassilev V, Ledent E, Heineman TC. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults [J]. J Infect Dis, 2012, 206(8): 1280-1290.
  • 10Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales [J]. Vaccine, 2001, 19 (23-24): 3076-3090.

共引文献32

同被引文献16

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部